Lead candidates from Rakovina Therapeutics' kt-2000 series exhibit potency comparable to FDA-approved PARP-inhibitors and potent anti-cancer

Micron Technologies has submitted its N95 Model 8800 face masks to NIOSH and is confident it will obtain NIOSH certification...

Dr. Cherrington is an accomplished life science executive with a record of success bringing drug candidates through to commercialization...

Many additional IP anomalies have been detected both historically and in a recent survey and will be tested with the present drill programme

Stratabound looks forward to more U.S. investor participation in the future of our Company.

"We're excited to join other industry leaders to provide a highly trusted verifiable credential that will support the global recovery,"

The company will focus on the development of novel DNA-damage repair (DDR) inhibitors for the treatment of cancer

DBD may earn up to a 100% interest in the Project by undertaking work and payments in three defined earn-in stages.

Access to such an engaged visitor base presents a sizeable new growth channel of opportunity for Marble to empower Canadians...